[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609901":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":65,"collaborators":19,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":19,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":19,"maxAge":19,"enrollmentInfo":75,"targetDuration":19,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"PepGen Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PGN-EDODM1","EXPERIMENTAL","Participants will receive doses of PGN-EDODM1 once every 4 weeks (Q4W)",[13],"Drug: PGN-EDODM1",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered by intravenous (IV) infusion",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"PepGen Patient Advocacy","CONTACT","781-797-0979","clinicaltrials@pepgen.com",[27,44,55],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"University of Calgary","RECRUITING","Calgary","Alberta","T2N 4Z6","Canada","CA",{"type":36,"coordinates":37},"Point",[38,39],-114.08529,51.05011,{"lat":39,"lon":38},[42],{"name":43,"role":23,"phone":24,"phoneExt":19,"email":25},"Patient Advocacy",{"facility":45,"status":29,"city":46,"state":47,"zip":19,"country":33,"countryCode":34,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"Ottawa Hospital Research Institute","Ottawa","Ontario",{"type":36,"coordinates":49},[50,51],-75.69812,45.41117,{"lat":51,"lon":50},[54],{"name":43,"role":23,"phone":19,"phoneExt":19,"email":25},{"facility":56,"status":29,"city":57,"state":19,"zip":19,"country":33,"countryCode":34,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"CIUSSS du Saguenay-Lac-Saint-Jean","Saguenay",{"type":36,"coordinates":59},[60,61],-71.06573,48.41675,{"lat":61,"lon":60},[64],{"name":43,"role":23,"phone":19,"phoneExt":19,"email":25},{"type":66,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100609901","phase-2-an-open-label-extension-study-of-pgn-edodm1-in-people-with-myotonic-dystrophy-type-1-freedom-ole-100609901",false,"NCT07220603","An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)","An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)","Inclusion Criteria:\n\n* Participant has completed a prior study with PGN-EDODM1\n\nExclusion Criteria:\n\n* Abnormal laboratory tests at screening considered clinically significant by the Investigator\n* Use of an investigational drug (other than PGN-EDODM1), device, or product, within 30 days or 5 half-lives of the study drug (whichever is longer) prior to study entry","ALL",{"count":76,"type":77},48,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.",[83],"Myotonic Dystrophy 1",[85,83,86,87,9,88,89,90,91,92,93,94,95,96,97,98],"DM1","Myotonic Dystrophy","PepGen","Myotonic Muscular Dystrophy","Steinhert's Disease","Myotonic Dystrophies","Genetic Diseases, Inborn","Neuromuscular Diseases","Nervous System Diseases","Musculoskeletal Diseases","Myotonic Disorders","Muscular Disorders, Atrophic","Heredodegenerative Disorders, Nervous System","Muscular Diseases","2026-03-26",{"date":101,"type":102},"2026-03-30","ACTUAL",{"date":104,"type":102},"2025-12-23",{"date":106,"type":77},"2029-01",{"name":5,"class":6},3]